Online inquiry

IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7938MR)

This product GTTS-WQ7938MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7938MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ607MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ14506MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ15408MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ8529MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ1959MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ8482MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ15493MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ154MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 124I_WX-G250
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW